CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $14.75 per share. Altus Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock to cover over-allotments, if any. All of the shares are being offered by Altus Pharmaceuticals. Merrill Lynch & Co. and Morgan Stanley & Co. are joint book-running managers for the offering. Cowen and Company and Leerink Swann & Company are co-managers for the offering.
